Our overall gross margin, which stood at 24.1%, 21.4%, and 22.1% for the respective periods, respectively, is affected by the components of our service and solution offerings and their respective margin.
Financial Information · p. 318
The average revenue per key customer decreased by 9.4% to RMB24.5 million in 2023, primarily due to a decrease in the average revenue contribution of key customers that primarily purchased our Contact Center SaaS services, mainly because the introduction of LLMs weakened the interest of our key customers in our Contact Center SaaS services, which did not yet fully integrate LLMs.
Our revenue decreased by 4.0% from RMB350.8 million in 2022 to RMB336.8 million in 2023, primarily due to a 10.4% decrease in average revenue per customer from approximately RMB528.0 thousand in 2022 to RMB474.0 thousand in 2023.
Summary · p. 12
Our profit for the year decreased by 9.4% from RMB54.0 million in 2022 to RMB48.9 million in 2023, primarily due to (i) decrease in our revenue from RMB350.8 million in 2022 to RMB336.8 million in 2023, and (ii) increase in our cost of sales from RMB149.8 million in 2022 to RMB156.6 million in 2023, partially offset by the decrease of fair value losses on financial liabilities at FVTPL from RMB67.1 million in 2022 to RMB45.4 million in 2023.
Summary · p. 14
The healthcare industry experienced a general decline in terms of the amount of financing in recent years, forcing industry players (including our customers) to reduce their NCE development pipeline to focus on fewer pipeline products with more potential of commercialization success.
During the Track Record Period, our profitability and gross profit margin were affected by the fact that some of our postpartum centers were at the initial ramp-up stage.
Financial Information · p. 347
Out of the 18 newly added self-operated centers in 2024, nine were opened in the second half of 2024.
Financial Information · p. 349
For the year ended December 31, 2024, there was an increase in our rental and related costs as a percentage of our revenue compared to the year ended December 31, 2023 primarily due to the increased rental and related costs for hotel rooms as a result of (i) the room charges for hotel rooms we rented on a fixed-term basis for some of our new centers which had not been occupied; and (ii) a general increase in room charges per night.
For 2023 and 2024, we had 47 same stores, the aggregate sales revenue of which decreased by 21.2% from RMB369.2 million in 2023 to RMB290.8 million in 2024.
Business · p. 211
In addition, the increase in closed self-operated stores in 2024 was also attributable to market conditions, particularly the rapid surge in gold prices during certain periods of 2024, which led to a temporary reduction in demand for gold products as end consumers exercised increased caution in their purchase decisions, which put pressure on the sales performance of some of our self-operated stores.
Business · p. 207
The performances of our self-operated stores experienced a decline from 2023 to 2024, primarily because in 2024, the significant increase in gold prices adversely affected end consumer perception of affordability, leading to a certain degree of decline in their willingness to purchase gold jewelry.
For example, in 2022, consumers had to reduce dining out, which affected the catering industry, leading to a slowdown in the overall inventory turnover of condiments and a residual impact on the overall sales of condiments in 2023.
Financial Information · p. 268
Whilst these strategic adjustments had certain short-term impacts on our product sales in 2023 as we witnessed a decrease in revenue compared to 2022, they gradually took effect and we recorded a revenue growth in 2024.
Financial Information · p. 268
Our revenue from product sales increased from RMB22,815.1 million in 2023 to RMB25,127.8 million in 2024.
The decrease in our revenue from insurance transaction services from RMB1,628.6 million in 2023 to RMB1,377.8 million in 2024 was mainly attributable to the decrease in revenue from Niubao 100 platform from RMB1,101.1 million in 2023 to RMB864.6 million in 2024, which was further attributable to (i) the decrease in revenue generated from self-media traffic channels from RMB599.5 million in 2023 to RMB404.6 million in 2024 and (ii) to a lesser extent the decrease in revenue generated from licensed brokerages and agencies from RMB501.7 million in 2023 to RMB459.9 million in 2024.
Summary · p. 4
Furthermore, we enhanced cooperation with large licensed brokerages and agencies, for example Supplier E and Supplier H in 2024.
Our profit for the year decreased by RMB147.6 million, or 44.5%, from RMB332.1 million in 2023 to RMB184.5 million in 2024, mainly due to a decrease in the revenue derived from our cross-border social e-commerce business.
Summary · p. 11
Our total revenue decreased by RMB1,165.4 million, or 17.4%, from RMB6,694.7 million in 2023 to RMB5,529.3 million in 2024, primarily because in 2024, we adjusted personnel and resources to initiate our sales expansion into other under-penetrated areas within Europe, and to develop and promote our own brands under our cross-border social e-commerce business.
Summary · p. 14
In 2024, the depreciation of Japanese yen and South Korean won against Renminbi, and our reduced selling prices for certain products in such areas, led to our lower average selling price per order recognized in Renminbi in such markets.
Such fluctuation was primarily due to less sales and marketing efforts in Singapore in light of the optimization of cost structure in 2024, which was evidenced by a significant decrease in sales and marketing expenses related to the promotion of GASTROClear™ in Singapore.
Business · p. 400
The revenue generated from sales of LUNGClear™ increased from 2022 to 2023, and decreased from 2023 to 2024.
Our cost of sales as a percentage of revenue was 47.5%, 43.8% and 56.2% for the years ended December 31, 2022, 2023 and 2024, respectively.
In 2024, we recorded decreases in same store sales in all regions.
Business · p. 173
Such decreases were primarily due to a general change in consumer behavior to reduce expenses and frequencies of dining out given the current economic environment, which led to decreases in our table turnover rate and average spending per guest in all regions.
Business · p. 173
According to CIC, we outperformed the majority of our industry peers in terms same store sales growth in 2024.
Despite the increase in our gross profit from RMB1,017.4 million in 2023 to RMB1,027.3 million in 2024, our profit decrease from RMB387.9 million to RMB328.9 million during the same periods, primarily due to a significant increase in share-based payment expenses and the listing expenses recorded in 2024.
Summary · p. 15
As a result of the overall industry slowdown and intensified competition, our average GMV per store decreased from RMB1.6 million in 2023 to RMB1.4 million in 2024, and our average GMV per order decreased from RMB26 to RMB25.
Summary · p. 2
In 2024, our same-store GMV decreased by 10.6%, primarily due to the overall industry slowdown and intensified competition in 2024.
Our revenue grew from RMB11,085.7 million in 2022 to RMB18,610.8 million in 2023, and decreased to RMB9,923.9 million for 2024.
Summary · p. 6
During the Track Record Period, the average selling prices for our products experienced an overall downward trend with fluctuation, which was generally in line with the industry trend.
Financial Information · p. 371
The decrease in the gross profit margin of our N-type TOPCon cells in these periods was mainly due to the decrease in the average selling price of our N-type TOPCon cells, which reduced the price difference between silicon wafers and N-type TOPCon cells, and non-silicon costs did not decrease proportionally with the average selling price of our N-type TOPCon cells.
As a result, our sales volume of NCM batteries decreased from 2.9 GWh in 2022 to 1.5 GWh in 2023, and our revenue from the sales of NCM batteries decreased from RMB2,628.6 million in 2022 to RMB1,448.0 million in 2023.
Business · p. 326
The aggregate impairment in trade receivables and inventories in 2022 arising from the WM Customer Incident was RMB1,023.6 million.
Business · p. 326
However, we believe such impact was one-off in nature.
For the same years/period, the revenue generated from our retail operations amounted to approximately RMB888.5 million, RMB787.9 million, RMB688.6 million and RMB417.8 million, representing approximately 62.0%, 59.3%, 49.1% and 41.5% of our total revenue, respectively.
Summary · p. 1
Such change in revenue mix was mainly attributable to the impact of COVID-19 pandemic and cessation of sales of tobacco products on our retail operations and the change in food consumption behaviour of consumer and that we gradually focused more on our wholesale operations.
Summary · p. 1
Our revenue generated from retail operations amounted to RMB888.5 million, RMB787.9 million, RMB688.6 million and RMB417.8 million for FY2021, FY2022, FY2023 and 9M2024, respectively, representing 62.0%, 59.3%, 49.1% and 41.5% of our total revenue, respectively.
Our bulk sale customers include corporate and government entities, and they place orders with our Retail Stores or our sales team of our head office.
Business · p. 242
The number of our bulk sales customers decreased significantly during FY2023 and 9M2024 mainly driven by the easing of COVID-19 pandemic in the PRC.
However, following the lifting of restrictions with COVID-19 pandemic largely behind in the PRC, consumers in the PRC returned to more regular shopping habits, which led to the decrease in the number of our bulk sales customers.
For the nine months ended September 30, 2024, as a result of the general industry slowdown and increased competition as discussed above, we recorded smaller per-store GMV, per-store daily GMV, per-store number of cups sold, per-store daily number of cups sold, average GMV per order, average number of orders per store per day, and average daily GMV per newly opened franchised store as compared to the same period in 2023.
Business · p. 178
In response to these changes, we adjusted our business strategy to focus on improving the operating efficiency and business performance of our existing stores, while slowing down the pace of new store openings.
Our adjusted net profit (non-IFRS measures) decreased by 51.3% from RMB30.4 million for the six months ended June 30, 2023 to RMB14.8 million for the six months ended June 30, 2024, primarily because our profit from operations decreased by 88.0% from RMB20.9 million for the six months ended June 30, 2023 to RMB2.5 million for the six months ended June 30, 2024.
Summary · p. 9
Such decrease in profit from operations was mainly because (i) our revenue had relatively modest growth, which increased by 14.5% from RMB534.0 million for the six months ended June 30, 2023 to RMB611.5 million for the six months ended June 30, 2024, and (ii) our gross profit margin slightly decreased from 32.6% for the six months ended June 30, 2023 to 30.0% for the six months ended June 30, 2024; as compared to (i) the relatively high increase in our selling expenses, which grew by 26.1% from RMB78.2 million for the six months ended June 30, 2023 to RMB98.6 million for the six months ended June 30, 2024, primarily due to the increase in expenses for promotion of our overall brand and offerings among customers, physicians and hospitals, and (ii) the relatively high increase in our research and development costs, which grew by 48.4% from RMB36.4 million for the six months ended June 30, 2023 to RMB54.0 million for the six months ended June 30, 2024, primarily due to the increase in technical and outsourcing service fees in relation to development of AI-based plugins.
Our same store sales for Xiaocaiyuan restaurants decreased by 11.4% in the eight months ended August 31, 2024 as compared to the same period in 2023.
Summary · p. 2
In the eight months ended August 31, 2024 as compared to the same period of 2023, our same store sales for Xiaocaiyuan restaurants decreased by 11.4% and our restaurant-level operating margins decreased from 21.3% to 17.8%, mainly due to (i) the base effect as a result of the rapid surge in spendings of consumers in China’s catering market during the first several months in 2023 following the gradual phasing-out of the COVID-19 pandemic, which was in line with the spending trends in other consumer sectors according to Frost & Sullivan; (ii) our adjustments to the menu item prices to accommodate the preferences of consumers, demonstrating our long-term commitment to bringing cost-effective experience to our customers; for example, in the eight months ended August 31, 2024 as compared to the year of 2023, (a) the average price of Cauldron Cooked Spring Chicken decreased from RMB64.5 to RMB54.9, and (b) the average price of Slate Garlic Prawn decreased from RMB55.7 to RMB53.3; and (iii) some of the newly opened Xiaocaiyuan restaurants in the eight months ended August 31, 2024 were still in their ramp-up period as of August 31, 2024.
During the Track Record Period, our revenue decreased by RMB1,146.8 million or 6.8% from RMB16,871.0 million to RMB15,724.2 million for the year ended December 31, 2022 and increased by RMB4,484.4 million or 28.5% to RMB20,208.6 million for the year ended December 31, 2023.
Financial Information · p. 440
Our net profit margin decreased from 1.2% for the year ended December 31, 2023 to 0.5% for the six months ended June 30, 2024 primarily due to an increase in our net realized loss on Au (T+D) contracts and gold loans, which in turn, was a result of a material increase in gold price during the first half of 2024.
Business · p. 216
Our sales volume of gold products decreased by 10.4% for the six months ended June 30, 2024 when compared to the same period in 2023, which was better than the industry contraction of 20.2% (as aforementioned).
Our revenue decreased by 13.9% from RMB1,307.3 million in 2021 to RMB1,125.4 million in 2022, primarily due to a decrease of RMB163.3 million in revenue from sales of goods.
Summary · p. 17
Our revenue generated from sales of enoxaparin API decreased by 61.3% from RMB121.8 million in 2021 to RMB47.1 million in 2022, which was mainly due to a geopolitical conflict which affected our sales to a client in Ukraine.
Summary · p. 18
Our revenue from oncology and hematology therapeutic areas declined during the Track Record Period primarily because most of our marketed products in these therapeutics areas are biosimilars or generic small molecule drugs subject to the impact of the VBP schemes, which has exerted downward pressure on the prices and sales volume of relevant products during the Track Record Period.